The association of soluble cluster of differentiation 36 with metabolic diseases: A potential biomarker and therapeutic target
The association of soluble cluster of differentiation 36 with metabolic diseases: A potential biomarker and therapeutic target
复制标题
DOI：
10.1002/pdi3.9
复制
发表时间：
2023-06
期刊：
影响因子：
--
通讯作者：
Yun Li;Yaxi Chen;X. Ruan
中科院分区：
文献类型：
--
作者：
Yun Li;Yaxi Chen;X. Ruan
分化簇36（CD36），也称为脂肪酸转位酶，在代谢性疾病的发生和进展中起着重要作用。可溶性CD 36（sCD 36）是CD 36的一种循环形式，在人血浆中鉴定。目前的研究表明，sCD 36是2型糖尿病（T2DM）和动脉粥样硬化风险的早期生物标志物，并可能直接或间接地作为器官交叉的关键分子。本文综述了sCD 36的细胞来源、分子结构、产生机制、功能及其调控因子。我们强调了sCD 36与高脂血症、代谢性炎症、T2DM、心血管疾病、非酒精性脂肪性肝病、糖尿病肾病和肥胖的相关性。这些研究表明，sCD 36可能是儿童代谢性疾病的一个有用的生物标志物，也是预防代谢性疾病的一个潜在的治疗靶点。
A cluster of differentiation 36 (CD36), also known as fatty acid translocase, plays an important role in developing and progressing metabolic diseases. Soluble CD36 (sCD36), a circulating form of CD36, is identified in human plasma. Current studies have demonstrated that sCD36 is an early biomarker of type 2 diabetes (T2DM) and atherosclerosis risk and may act as a key molecule in organ cross‐talks directly or indirectly. This review summarizes the cell sources, molecular structure, potential production mechanism, functions, and regulators of sCD36. We highlight the association of sCD36 with hyperlipidemia, metabolic inflammation, T2DM, cardiovascular disease, non‐alcoholic fatty liver disease, diabetic kidney disease, and obesity. These studies suggest that sCD36 could be a useful biomarker for metabolic diseases in children and a potential therapeutic target in preventing metabolic diseases.